A possible explanation is that response to chemotherapy is enhanced by IGF-IR targeting only in a subset of tumors, following the well-known precedent that adding EGFR inhibitors to chemotherapy in lung cancer is only helpful in tumors with EGFR mutations10,11. This evidence concerns the gene EGFR and lung carcinoma.